<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04498260</url>
  </required_header>
  <id_info>
    <org_study_id>NP888/2016</org_study_id>
    <nct_id>NCT04498260</nct_id>
  </id_info>
  <brief_title>Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture</brief_title>
  <official_title>Prospective, Randomized Trial of Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture After Endoscopic Submucosal Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic resection of superficial esophageal neoplasms is already a reality and presents&#xD;
      important advantages when compared to esophagectomy as fewer complications and better quality&#xD;
      of life. However, extensive resections can lead to difficult-to-manage stenoses. There are&#xD;
      several therapies available in order to prevent this stenosis but, to date, there is no&#xD;
      definition of the gold standard.&#xD;
&#xD;
      The objective of this study was to compare the use of intralesional steroid injection versus&#xD;
      oral prednisolone after endoscopic submucosal dissection and to evaluate the stenosis rate,&#xD;
      number of dilations to resolve the stenosis and complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic resection of superficial esophageal neoplasms is widely used as an alternative to&#xD;
      esophagectomy, since it is less invasive, besides presenting good clinical results. Compared&#xD;
      with esophagectomy, patients submitted to endoscopic resection present shorter&#xD;
      hospitalization time, lower incidence of complications and better quality of life in the long&#xD;
      term.&#xD;
&#xD;
      However, repair of esophageal ulcer, caused by endoscopic resection, which occupies three&#xD;
      quarters or more of the circumference of the organ, can result in the formation of stenosis.&#xD;
&#xD;
      In the past, there was no consensus on the use of preventive therapies for esophageal&#xD;
      stenosis after extensive ESD. However, Oliveira et al recently demonstrated through&#xD;
      systematic review and meta-analysis that the use of these therapies reduces the rate of&#xD;
      stenosis (40% on average), decreased the number of dilations to resolve the stenosis (8&#xD;
      sessions less ), Without altering the number of complications.&#xD;
&#xD;
      Theoretically, corticosteroids are the most appropriate choice due to their mechanism of&#xD;
      action, modulating wound healing by preventing inflammation, by reducing prolyl hydroxylase,&#xD;
      which helps reduce collagen production.&#xD;
&#xD;
      However, treatment with corticosteroids, especially at high oral doses, can cause several&#xD;
      adverse effects, such as immunosuppression, diabetes, psychiatric disorders, osteoporosis,&#xD;
      optic lesion and peptic ulcer. Thus, the use of local corticosteroid injection could minimize&#xD;
      these side effects. However, local injection implies risks of bleeding and perforation, and&#xD;
      is of limited use in patients receiving anticoagulant or antiplatelet therapy.&#xD;
&#xD;
      The objective of this study was to compare the local corticosteroid injection and the use of&#xD;
      oral corticosteroids to prevent stenosis after extensive submucosal endoscopic resection of&#xD;
      superficial esophageal carcinoma, in relation to the stenosis rate, number of dilations&#xD;
      necessary to resolve the stenosis and frequency of complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">June 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Stenosis rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Stenosis to the passage of the standard endoscopic (9.8 mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late Stenosis rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Stenosis to the passage of the standard endoscopic (9.8 mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early resistance rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Resistance to the passage of the standard endoscopic (9.8 mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late resistance rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Resistance to the passage of the standard endoscopic (9.8 mm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dilations to solve the stenosis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of endoscopic dilations (Savary or balloon)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complications</measure>
    <time_frame>24 weeks</time_frame>
    <description>Complications related to the procedure and preventive therapy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Esophageal Stenosis</condition>
  <arm_group>
    <arm_group_label>Local steroid-triamcinolone acetonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local steroid (triamcinolone acetonide) injection to the ulcer immediately after ESD. Total amount of injected triamcinolone is 100 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral steroid-predonisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(predonisolone) administration three days after ESD. Predonisolone is administered over 8 weeks, started at 30 mg/day and tapered 30, 30, 25, 25, 20, 15, 10 and 5 every 7 days, totaling 8 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local steroid - triamcinolone acetonide</intervention_name>
    <description>(triamcinolone acetonide)</description>
    <arm_group_label>Local steroid-triamcinolone acetonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral steroid - predonisolone</intervention_name>
    <description>(predonisolone)</description>
    <arm_group_label>Oral steroid-predonisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of superficial esophageal neoplasm submitted to submucosal&#xD;
             endoscopic resection greater than 3/4 of the organ circumference;&#xD;
&#xD;
          -  Absence of lymph node or distant metastases, evaluated through echoendoscopy, CT and&#xD;
             PET-CT;&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of invasive esophageal neoplasia&#xD;
&#xD;
          -  Hepatical cirrhosis&#xD;
&#xD;
          -  Diabetes mellitus with fasting glycemia above 200mg%&#xD;
&#xD;
          -  Use of corticosteroids in the 30 days prior to ESD&#xD;
&#xD;
          -  INR&gt; 1.5&#xD;
&#xD;
          -  Platelet count less than 50,000&#xD;
&#xD;
          -  Active gastrointestinal ulcer&#xD;
&#xD;
          -  Severe psychiatric illness&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  History of allergy or hypersensitivity to corticosteroids or proton pump inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fauze Maluf-Filho, PhD</last_name>
    <phone>55 11 99191-9014</phone>
    <email>fauze.maluf@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joel F Oliveira, MD</last_name>
    <phone>55 11 96382-0289</phone>
    <email>jfoliveira1@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Câncer do Estado de São Paulo - ICESP</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fauze Fauze-Maluf, MD, PHD</last_name>
      <phone>5511991919014</phone>
      <email>fauze.maluf@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Fauze Maluf-FIlho, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endoscopy submucosal dissection</keyword>
  <keyword>ESD</keyword>
  <keyword>esophageal stenosis</keyword>
  <keyword>esophageal stricture</keyword>
  <keyword>steroid injection</keyword>
  <keyword>oral prednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

